Why the study?
Patients with T2DM can develop chylomicrons from poor glycemic control or genetic defects reducing LPL activity, and the study aimed to describe tirzepatide as a novel treatment in a patient with HeLPL, T2DM, and persistent chylomicrons despite maximal standard therapy.
Does tirzepatide reduce triglyceride levels and resolve chylomicronemia in a patient with T2DM and heterozygosity for lipoprotein lipase deficiency?
Does tirzepatide reduce triglyceride levels and resolve chylomicronemia in a patient with T2DM and heterozygosity for lipoprotein lipase deficiency?
Tirzepatide may be an effective novel therapy for reducing severe hypertriglyceridemia and resolving chylomicronemia in patients with T2DM and genetic lipoprotein lipase deficiency.
Answers are grounded in this paper and cite their sources.
Tirzepatide was associated with chylomicron reduction in this HeLPL-T2DM case; leaves open efficacy in broader populations.
Background/Objective: A patient with well-controlled type 2 diabetes mellitus (T2DM) and a heterozygote for lipoprotein lipase deficiency (HeLPL) presented with chronic chylomicrons (CMs). Some patients with T2DM can develop CMs due to poor glycemic control or genetic defects that result in a decrease in the lipoprotein lipase (LPL) activity. This study aimed to describe a patient with HeLPL with T2DM and persistent CM on maximal standard lipid-lowering therapy who then used tirzepatide as a novel way to treat CM. Case Report: A patient with well-controlled T2DM with persistent CM and HeLPL was treated with tirzepatide and titrated to 15 mg/week, resulting in resolution of his CM (triglyceride [TG] level, <850 mg/dL) with a 58% reduction in the serum TG level after 2 months and then an 86% reduction after 5 months of therapy. His A1C level and body weight decreased from 6.9% to 6.3% and by 12 lbs in 2 months and then to 5.6% and by 20 lbs after 5 months, respectively. Discussion: The resolution of CM and reduction in the TG level by tirzepatide cannot be solely explained by an improvement in glycemic control or a decrease in body weight but may also be related to other effects of tirzepatide. Conclusion: Tirzepatide caused a significant decrease in the TG level in a patient with CM, T2DM, and HeLPL. The mechanism(s) underlying this effect is not completely understood but warrants further study.
No takes yet. Share an insight, caveat, or question.
Stephan P. Babirak (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: